Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Senzime AB ( (SE:SEZI) ) has shared an update.
Senzime AB has launched the EMGINE Sirius software suite, an innovative enhancement to its TetraGraph® system, which will be presented at the PostGraduate Assembly in Anesthesiology in New York. This new release, developed from extensive patient data and clinical collaborations, includes features like the TetraGraph Intubation Readiness Indicator and personalized neuromuscular monitoring, promising improved safety and efficiency in surgical procedures. The TetraGraph system, already widely used in various hospitals, is further validated by a Mayo Clinic study showing its superiority in detecting optimal intubation conditions, reinforcing Senzime’s position as a leader in neuromuscular monitoring technology.
The most recent analyst rating on (SE:SEZI) stock is a Hold with a SEK4.50 price target. To see the full list of analyst forecasts on Senzime AB stock, see the SE:SEZI Stock Forecast page.
More about Senzime AB
Senzime is a leading medical device company established in 1999, specializing in precision-based monitoring systems that enhance perioperative patient safety. Their flagship product, the TetraGraph® system, is utilized globally to monitor neuromuscular transmission during surgery, ensuring accurate dosing of paralytic drugs and improving patient outcomes. Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market and the US OTCQX Market.
Average Trading Volume: 402,287
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK756.2M
See more insights into SEZI stock on TipRanks’ Stock Analysis page.